Literature DB >> 25944917

EphB1 Suppression in Acute Myelogenous Leukemia: Regulating the DNA Damage Control System.

K R Kampen1, F J G Scherpen1, G Garcia-Manero2, H Yang2, G J L Kaspers3, J Cloos3, C M Zwaan4, M M van den Heuvel-Eibrink4, S M Kornblau2, E S J M De Bont5.   

Abstract

UNLABELLED: Loss of ephrin receptor (EphB1) expression may associate with aggressive cancer phenotypes; however, the mechanism of action remains unclear. To gain detailed insight into EphB1 function in acute myelogenous leukemia (AML), comprehensive analysis of EphB1 transcriptional regulation was conducted. In AML cells, EphB1 transcript was inversely correlated with EphB1 promoter methylation. The presence of EphB1 allowed EfnB1 ligand-mediated p53 DNA binding, leading to restoration of the DNA damage response (DDR) cascade by the activation of ATR, Chk1, p53, p21, p38, CDK1(tyr15), and Bax, and downregulation of HSP27 and Bcl2. Comparatively, reintroduction of EphB1 expression in EphB1-methylated AML cells enhanced the same cascade of ATR, Chk1, p21, and CDK1(tyr15), which consequently enforced programmed cell death. Interestingly, in pediatric AML samples, EphB1 peptide phosphorylation and mRNA expression were actively suppressed as compared with normal bone marrow, and a significant percentage of the primary AML specimens had EphB1 promoter hypermethylation. Finally, EphB1 repression associated with a poor overall survival in pediatric AML. Combined, the contribution of EphB1 to the DDR system reveals a tumor-suppressor function for EphB1 in pediatric AML. IMPLICATIONS: The tumor-suppressor function of EphB1 is clinically relevant across many malignancies, suggesting that EphB1 is an important regulator of common cancer cell transforming pathways. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25944917      PMCID: PMC4983719          DOI: 10.1158/1541-7786.MCR-14-0660-T

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  35 in total

Review 1.  Eph receptors and ephrins in cancer: bidirectional signalling and beyond.

Authors:  Elena B Pasquale
Journal:  Nat Rev Cancer       Date:  2010-03       Impact factor: 60.716

2.  Ligand binding induces Cbl-dependent EphB1 receptor degradation through the lysosomal pathway.

Authors:  Katrin Fasen; Douglas Pat Cerretti; Uyen Huynh-Do
Journal:  Traffic       Date:  2007-12-19       Impact factor: 6.215

3.  The receptor tyrosine kinase EphA2 is a direct target gene of hypermethylated in cancer 1 (HIC1).

Authors:  Bénédicte Foveau; Gaylor Boulay; Sébastien Pinte; Capucine Van Rechem; Brian R Rood; Dominique Leprince
Journal:  J Biol Chem       Date:  2011-12-19       Impact factor: 5.157

4.  Higher expression of EphA2 and ephrin-A1 is related to favorable clinicopathological features in pathological stage I non-small cell lung carcinoma.

Authors:  Masashi Ishikawa; Ryo Miyahara; Makoto Sonobe; Marika Horiuchi; Toshi Mennju; Ei Nakayama; Masashi Kobayashi; Ryutaro Kikuchi; Jiro Kitamura; Naoto Imamura; Cheng-Long Huang; Hiroshi Date
Journal:  Lung Cancer       Date:  2012-01-10       Impact factor: 5.705

5.  Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome.

Authors:  S Boehrer; L Adès; N Tajeddine; W K Hofmann; S Kriener; G Bug; O G Ottmann; M Ruthardt; L Galluzzi; C Fouassier; M Tailler; K A Olaussen; C Gardin; V Eclache; S de Botton; S Thepot; P Fenaux; G Kroemer
Journal:  Oncogene       Date:  2009-04-27       Impact factor: 9.867

6.  Translocations involving 6p22 in acute myeloid leukaemia at relapse: breakpoint characterization using microarray-based comparative genomic hybridization.

Authors:  Joëlle Tchinda; Trijnie Dijkhuizen; Pieter van der Vlies Pv; Klaas Kok; Jürgen Horst
Journal:  Br J Haematol       Date:  2004-08       Impact factor: 6.998

7.  Gene expression profiling of pediatric acute myelogenous leukemia.

Authors:  Mary E Ross; Rami Mahfouz; Mihaela Onciu; Hsi-Che Liu; Xiaodong Zhou; Guangchun Song; Sheila A Shurtleff; Stanley Pounds; Cheng Cheng; Jing Ma; Raul C Ribeiro; Jeffrey E Rubnitz; Kevin Girtman; W Kent Williams; Susana C Raimondi; Der-Cherng Liang; Lee-Yung Shih; Ching-Hon Pui; James R Downing
Journal:  Blood       Date:  2004-06-29       Impact factor: 22.113

8.  EFNA1 ligand and its receptor EphA2: potential biomarkers for hepatocellular carcinoma.

Authors:  Xiang-Dan Cui; Mi-Jin Lee; Goung-Ran Yu; In-Hee Kim; Hee-Chul Yu; Eun-Young Song; Dae-Ghon Kim
Journal:  Int J Cancer       Date:  2010-02-15       Impact factor: 7.396

9.  Expression of EphA2 in human astrocytic tumors: correlation with pathologic grade, proliferation and apoptosis.

Authors:  Xia Li; Yingmei Wang; Yazhou Wang; Haining Zhen; Hao Yang; Zhou Fei; Jianning Zhang; Weiping Liu; Yangang Wang; Xiang Zhang
Journal:  Tumour Biol       Date:  2007-05-21

Review 10.  The DNA damage response and cancer therapy.

Authors:  Christopher J Lord; Alan Ashworth
Journal:  Nature       Date:  2012-01-18       Impact factor: 49.962

View more
  7 in total

1.  Truncation- and motif-based pan-cancer analysis reveals tumor-suppressing kinases.

Authors:  Andrew M Hudson; Natalie L Stephenson; Cynthia Li; Eleanor Trotter; Adam J Fletcher; Gitta Katona; Patrycja Bieniasz-Krzywiec; Matthew Howell; Chris Wirth; Simon Furney; Crispin J Miller; John Brognard
Journal:  Sci Signal       Date:  2018-04-17       Impact factor: 8.192

Review 2.  Paradoxes of the EphB1 receptor in malignant brain tumors.

Authors:  Wenqiang Wei; Hongju Wang; Shaoping Ji
Journal:  Cancer Cell Int       Date:  2017-02-08       Impact factor: 5.722

Review 3.  Orange is the new black: Kinases are the new master regulators of tumor suppression.

Authors:  Elvira An; John Brognard
Journal:  IUBMB Life       Date:  2018-12-11       Impact factor: 3.885

Review 4.  Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia.

Authors:  Kalpana K Bhanumathy; Amrutha Balagopal; Frederick S Vizeacoumar; Franco J Vizeacoumar; Andrew Freywald; Vincenzo Giambra
Journal:  Cancers (Basel)       Date:  2021-01-07       Impact factor: 6.639

5.  RNA sequencing and functional studies of patient-derived cells reveal that neurexin-1 and regulators of this pathway are associated with poor outcomes in Ewing sarcoma.

Authors:  Elizabeth Ann Roundhill; Mariona Chicon-Bosch; Lee Jeys; Michael Parry; Kenneth S Rankin; Alastair Droop; Susan Ann Burchill
Journal:  Cell Oncol (Dordr)       Date:  2021-08-17       Impact factor: 6.730

6.  Construction of three-gene-based prognostic signature and analysis of immune cells infiltration in children and young adults with B-acute lymphoblastic leukemia.

Authors:  Chunli Xiang; Jie Wu; Liang Yu
Journal:  Mol Genet Genomic Med       Date:  2022-05-23       Impact factor: 2.473

7.  Peptide microarray profiling identifies phospholipase C gamma 1 (PLC-γ1) as a potential target for t(8;21) AML.

Authors:  Hasan Mahmud; Frank J G Scherpen; Tiny Meeuwsen de Boer; Harm-Jan Lourens; Caroline Schoenherr; Matthias Eder; Michaela Scherr; Victor Guryev; Eveline S De Bont
Journal:  Oncotarget       Date:  2017-06-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.